rs10034450
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001083.4(PDE5A):c.1632+4466T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.263 in 151,988 control chromosomes in the GnomAD database, including 5,391 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.26 ( 5391 hom., cov: 31)
Consequence
PDE5A
NM_001083.4 intron
NM_001083.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -2.17
Publications
8 publications found
Genes affected
PDE5A (HGNC:8784): (phosphodiesterase 5A) This gene encodes a cGMP-binding, cGMP-specific phosphodiesterase, a member of the cyclic nucleotide phosphodiesterase family. This phosphodiesterase specifically hydrolyzes cGMP to 5'-GMP. It is involved in the regulation of intracellular concentrations of cyclic nucleotides and is important for smooth muscle relaxation in the cardiovascular system. Alternative splicing of this gene results in three transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-1.05).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.366 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PDE5A | NM_001083.4 | c.1632+4466T>C | intron_variant | Intron 11 of 20 | ENST00000354960.8 | NP_001074.2 | ||
| PDE5A | NM_033430.3 | c.1506+4466T>C | intron_variant | Intron 11 of 20 | NP_236914.2 | |||
| PDE5A | NM_033437.4 | c.1476+4466T>C | intron_variant | Intron 11 of 20 | NP_246273.2 | |||
| PDE5A | XM_017008791.3 | c.1632+4466T>C | intron_variant | Intron 11 of 14 | XP_016864280.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.263 AC: 39921AN: 151872Hom.: 5388 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
39921
AN:
151872
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.263 AC: 39955AN: 151988Hom.: 5391 Cov.: 31 AF XY: 0.261 AC XY: 19385AN XY: 74276 show subpopulations
GnomAD4 genome
AF:
AC:
39955
AN:
151988
Hom.:
Cov.:
31
AF XY:
AC XY:
19385
AN XY:
74276
show subpopulations
African (AFR)
AF:
AC:
8688
AN:
41476
American (AMR)
AF:
AC:
4045
AN:
15260
Ashkenazi Jewish (ASJ)
AF:
AC:
691
AN:
3466
East Asian (EAS)
AF:
AC:
1952
AN:
5136
South Asian (SAS)
AF:
AC:
846
AN:
4818
European-Finnish (FIN)
AF:
AC:
2762
AN:
10572
Middle Eastern (MID)
AF:
AC:
63
AN:
294
European-Non Finnish (NFE)
AF:
AC:
19972
AN:
67956
Other (OTH)
AF:
AC:
586
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1533
3066
4598
6131
7664
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
414
828
1242
1656
2070
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
863
AN:
3476
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.